Human epidermal growth factor receptor 2 (HER2): Translating the lab to the clinic

Cesar Santa-Maria; Sarika Jain; William J. Gradishar

doi:10.1007/978-3-319-41761-5_5

Human epidermal growth factor receptor 2 (HER2): Translating the lab to the clinic

Cesar Santa-Maria, Sarika Jain, William J. Gradishar

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

The overexpression/amplification of HER2 has been classically associated with poor outcomes in breast cancer. However, with the advent of targeted therapies this may no longer be the case. A number of agents that are directed at the HER2 molecule or downstream of it have now become available. Evidence from clinical trials seems to suggest that these agents are potent. More importantly, they exert an additive/synergistic effect resulting in improved patient outcomes. In this chapter, we review the available evidence for the use of these agents in metastatic and early breast cancer. We also briefly discuss the mechanisms that have been implicated in the development of resistance to anti-HER2 therapies.

Original language	English (US)
Title of host publication	Molecular Pathology of Breast Cancer
Publisher	Springer International Publishing
Pages	59-70
Number of pages	12
ISBN (Electronic)	9783319417615
ISBN (Print)	9783319417592
DOIs	https://doi.org/10.1007/978-3-319-41761-5_5
State	Published - Jan 1 2016
Externally published	Yes

Keywords

HER2
Metastatic
Neoadjuvant
Pertuzumab
T-DM1
Trastuzumab

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-3-319-41761-5_5

Cite this

@inbook{f9c3e4c1fe344ea0973be705cb5bc48a,

title = "Human epidermal growth factor receptor 2 (HER2): Translating the lab to the clinic",

abstract = "The overexpression/amplification of HER2 has been classically associated with poor outcomes in breast cancer. However, with the advent of targeted therapies this may no longer be the case. A number of agents that are directed at the HER2 molecule or downstream of it have now become available. Evidence from clinical trials seems to suggest that these agents are potent. More importantly, they exert an additive/synergistic effect resulting in improved patient outcomes. In this chapter, we review the available evidence for the use of these agents in metastatic and early breast cancer. We also briefly discuss the mechanisms that have been implicated in the development of resistance to anti-HER2 therapies.",

keywords = "HER2, Metastatic, Neoadjuvant, Pertuzumab, T-DM1, Trastuzumab",

author = "Cesar Santa-Maria and Sarika Jain and Gradishar, {William J.}",

year = "2016",

month = jan,

day = "1",

doi = "10.1007/978-3-319-41761-5_5",

language = "English (US)",

isbn = "9783319417592",

pages = "59--70",

booktitle = "Molecular Pathology of Breast Cancer",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Human epidermal growth factor receptor 2 (HER2)

T2 - Translating the lab to the clinic

AU - Santa-Maria, Cesar

AU - Jain, Sarika

AU - Gradishar, William J.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The overexpression/amplification of HER2 has been classically associated with poor outcomes in breast cancer. However, with the advent of targeted therapies this may no longer be the case. A number of agents that are directed at the HER2 molecule or downstream of it have now become available. Evidence from clinical trials seems to suggest that these agents are potent. More importantly, they exert an additive/synergistic effect resulting in improved patient outcomes. In this chapter, we review the available evidence for the use of these agents in metastatic and early breast cancer. We also briefly discuss the mechanisms that have been implicated in the development of resistance to anti-HER2 therapies.

AB - The overexpression/amplification of HER2 has been classically associated with poor outcomes in breast cancer. However, with the advent of targeted therapies this may no longer be the case. A number of agents that are directed at the HER2 molecule or downstream of it have now become available. Evidence from clinical trials seems to suggest that these agents are potent. More importantly, they exert an additive/synergistic effect resulting in improved patient outcomes. In this chapter, we review the available evidence for the use of these agents in metastatic and early breast cancer. We also briefly discuss the mechanisms that have been implicated in the development of resistance to anti-HER2 therapies.

KW - HER2

KW - Metastatic

KW - Neoadjuvant

KW - Pertuzumab

KW - T-DM1

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=85009673250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009673250&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-41761-5_5

DO - 10.1007/978-3-319-41761-5_5

M3 - Chapter

AN - SCOPUS:85009673250

SN - 9783319417592

SP - 59

EP - 70

BT - Molecular Pathology of Breast Cancer

PB - Springer International Publishing

ER -

Human epidermal growth factor receptor 2 (HER2): Translating the lab to the clinic

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this